Incendia Therapeutics
PrivateLast Round
Convertible Debt
Apr 18, 2024
Total Funding Raised
$67.31M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Incendia Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Convertible Debt round in April 2024.
Incendia Therapeutics is a biotechnology company that develops innovative anti-cancer therapies designed to reprogram the tumor microenvironment to enhance treatment efficacy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Incendia Therapeutics Comparables
Compare Incendia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alixia | 87% | |
| ImmunoGenesis | 83% | |
| Sonata Therapeutics | 83% |
For institutional investors. Book with your work email.
Incendia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Apr 18, 2024 | ||||
| Series A | Nov 3, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Incendia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series A |
| Creacion Ventures | Series A |
| abrdn Inc. | Convertible Debt |
| Taiho Ventures | Series A |
| Northpond Ventures | Series A |
| Tekla Capital Management | Series A |
| Breakout Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 48% MoM.
- Jul 26, 2026
Monthly visitors grew 66% MoM, reaching 2K.
For institutional investors. Book with your work email.
Incendia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Incendia Therapeutics's valuation, stock price, and market status.
Is Incendia Therapeutics a public or private company?
Incendia Therapeutics is a private company.
What is the current stock price of Incendia Therapeutics?
Incendia Therapeutics is a private company, so its shares have no public market price. Caplight tracks Incendia Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Incendia Therapeutics worth (valuation)?
Valuation information for Incendia Therapeutics is not publicly available.
Can I buy Incendia Therapeutics stock?
Incendia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Incendia Therapeutics's last funding round?
Incendia Therapeutics's most recent funding round was Convertible Debt on April 18, 2024.
Who are the main investors in Incendia Therapeutics?
Key investors in Incendia Therapeutics include Taiho Ventures, Northpond Ventures, Pfizer Ventures, Pfizer Ventures.
Will Incendia Therapeutics IPO soon?
No public IPO plans have been announced for Incendia Therapeutics.
How can I track Incendia Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Incendia Therapeutics's shares on secondary markets.